News
We send the latest information from SMC Laboratories.
Introduction of Bile duct ligation (BDL)-induced primary biliary cirrhosis model
Today, we would like to introduce our bile duct ligation (BDL)-induced primary biliary cirrhosis disease model. This BDL model reproduces the pathological features of cholestatic liver disease, which leads to acute liver injury followed by liver inflammation and severe fibrosis. It is a great model for those looking to conduct in-vivo screening studies…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop simultaneously. Systemic scleroderma is a progressive, rare disease that causes fibrosis not only in the skin but also in tissues throughout the body, including the heart, lungs and kidneys. Pulmonary disease is a complication that has…
Announcement of webinar 【Creating high quality non-clinical study designs based on clinical trials】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place on February 16th (JST) from 10:30 AM. In this webinar series we have being looking at examples of both clinical NASH trials as well as non-clinical study designs. For the 4th installment in this series, we…
Introduction of positive control drug for kidney fibrosis mouse model
Today, we would like to introduce an established positive control – an ALK5 inhibitor – for our Unilateral Ureteral Obstruction (UUO)-induced renal fibrosis model. This ALK5 inhibitor has an inhibitory effect on the TGF-beta/ALK5 signaling pathway, which plays a central role in renal fibrosis. Due to its antifibrotic abilities, we have established the ALK5 inhibitor…
Introduction of our experiences in histopathological analyses for IPF
Today, we present some new histopathological data from our bleomycin-induced pulmonary fibrosis model, which is a clinically representative mouse model that can be used to conduct drug efficacy studies for idiopathic pulmonary fibrosis (IPF). Histological endpoints are necessary in order to accurately assess and understand the pathological changes that occur in the target tissue…
February 4th is World Cancer Day!
World Cancer Day was established on February 4th, 2000, at the World Summit Against Cancer for the New Millennium in Paris initiated by UICC (Union for International Cancer Control). It is a day where people all around the world come together and join in the fight against cancer by raising public awareness of the disease….
Study on the efficacy of dietary supplements in the mdx mouse published in bioRxiv.
SMC is proud to announce that GN Corporation (JPN) has published the results of their study using our pre-clinical services in bioRxiv. Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG) (Preethy et al., bioRxiv. 2022) This paper reviews the…
SMC announces Announcement of webinar 【High quality non-clinical study designs】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place next week on January 19th (JST) from 10:30 AM. In this webinar series we have being looking at examples of both clinical NASH trials as well as non-clinical study designs. For the 3rd installment in this…
NASH, the fastest growing cause of liver cancer
We wish you a Happy and Prosperous New Year! If you are currently planning to begin a project this year, we would love to support you in any way we can, including conducting one of our high quality pharmacology studies. Today, we would like to share with you a little bit about the…
SMC to attend Japan-UK Virtual Partnering!
We are pleased to announce that SMC Laboratories will be participating in the Japan-UK Virtual Partnering Online Event from January 23rd (Mon) to February 13th (Mon). The Japan-UK Virtual Partnering Online Event is organized by the Osaka Prefectural Government, and offers companies, start-ups and research institutions in Japan and the UK the opportunity to…